hero image

Biogen Idec to Present at the 26th Annual JPMorgan Healthcare Conference

January 3, 2008 Investor Relations

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec Inc. (NASDAQ:BIIB) announced today that its presentation and breakout session at the 26th Annual JPMorgan Healthcare Conference will be webcast live via the internet, on Monday, January 7, 2008 at 4:00 p.m. PT (7:00 p.m. ET). To access the live webcast, please visit Biogen Idec’s homepage, www.biogenidec.com. An archived version of the webcast will be available for two weeks following the presentation.

About Biogen Idec

Biogen Idec creates new standards of care in oncology, neurology and immunology. As a global leader in the development, manufacturing, and commercialization of novel therapies, Biogen Idec transforms scientific discoveries into advances in human healthcare. For product labeling, press releases and additional information about the company, please visit http://www.biogenidec.com.

 

Contact:

Biogen Idec
Heidi Brewster, 617-679-2757
Investor Relations

thumb
June 17, 2021
Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study

Global Phase 3 TOPAZ-1 study will evaluate the efficacy and safety of BIIB059, as compared to placebo, in active systemic lupus erythematosus (SLE) , a debilitating autoimmune disease which has limited treatment options Positive Phase 2 LILAC study efficacy results support the further evaluation of

thumb
June 16, 2021
Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer’s Disease

CAMBRIDGE, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Biogen Inc.  (Nasdaq: BIIB) today announced topline results from its Phase 2 TANGO study of gosuranemab (BIIB092), an investigational anti-tau antibody that was being evaluated as a potential treatment for Alzheimer’s disease.